A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease ...
Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or ...
Researchers from National Taiwan University Hospital and collaborating institutions have demonstrated that finerenone, a new-generation nonsteroidal mineralocorticoid receptor antagonist (MRA), ...
Please provide your email address to receive an email when new articles are posted on . Concurrent use of finerenone and empagliflozin reduced urine albumin-to-creatinine ratio for adults with CKD and ...
Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with ...
Two new analyses of the FINEARTS-HF trial may help physicians decide how, and for whom, finerenone can best be used to treat heart failure with mildly reduced or preserved ejection fraction ...
Finerenone's approval by the FDA to treat type 2 diabetes–associated chronic kidney disease was supported by data from the phase 2 FIDELIO-DKD trial; now, the results of FINEARTS-HF show real-world ...
The FDA has accepted for Priority Review the NDA for finerenone for chronic kidney disease in patients with type 2 diabetes. The Food and Drug Administration (FDA) has accepted for Priority Review the ...
Health and Me on MSN
New study finds common drug may slow kidney decline and reduce albuminuria in glomerular diseases
Glomerular diseases, if not treated, usually lead to kidney failure or chronic kidney disease. Now, a new study has found ...
Finerenone use in trial patients with HFpEF or HFmrEF increased hyperkalemia risk, especially in those with CKD. Finerenone use in patients with heart failure and preserved or mildly reduced ejection ...
Please provide your email address to receive an email when new articles are posted on . Mineralocorticoid receptor antagonists disrupt the renin-angiotensin-aldosterone system and provide beneficial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results